Loading...
As rates of methicillin resistance soar among the staphylococci, vancomycin is often the drug of choice for empirical anti-staph treatment; sometimes, because of its convenient dosing schedule in the presence of renal impairment, its use is continued even if isolates are susceptible to other drugs. A new study joins the body of evidence suggesting that vancomycin is a relatively poor choice for treating methicillin-susceptible Staphylococcus aureus (MSSA) infection.
Researchers evaluated treatment outcome in hemodialysis patients with bacteremic MSSA infection who were seen during a 7-year period at a single academic center where cefazolin was the preferred β-lactam drug for treating MSSA infection. Most infections were related to the dialys…